CAMBRIDGE, Mass., May 16, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that updated results from a Phase 1 study of the company's lead inhibitor of heat shock protein 90, IPI-504, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) or other advanced soft tissue sarcomas, will be presented at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO). This meeting will be held May 31 through June 3, 2008 at McCormick Place in Chicago, Ill.
